Latest news with #RoyalNorthShoreHospital
Sydney Morning Herald
5 days ago
- General
- Sydney Morning Herald
The downside of stocking up
More on the art of obtaining retail rewards (C8) now, with John Dawson of North Parramatta: 'In the early '60s my boss found a 2000-year supply of carbon paper in the stationery cabinet. The supplier used to give a pair of stockings with each box ordered by the stenographer.' 'Simon Dixon (C8) has enthralled us with a token multi-generation breakfast saga,' gushes Warren Finnan of West Ryde. 'We eagerly wait for the next episode in this exciting cereal!' 'Thank you to all those Good Samaritans who came to help my husband when he tripped on uneven tiling on the footpath outside 1 York Street last week,' writes Alison Stewart of Waitara, 'To the very patient lady who tried endlessly to contact triple zero but was told there was up to a two-hour wait! Then to the tattooed, dark-wavy-haired delivery cyclist who ran across the street to secure a taxi to drive hubby to Royal North Shore Hospital. Other office workers who passed by also helped. Thank you to all at RNSH, too.' Like Robert Hosking, Peter Miniutti of Ashbury is a fan of lugging park links: 'During early morning winter walks, filled dog-poo bags (C8) in the hoodie pocket is a wonderful way to keep your hand warm.' Stephen Tait of Rose Bay recalls that a pair of locals, emboldened by the success of obliterating a letterbox (C8) on the way to Woolwich Public School, 'dropped a Tom Thumb down the keyhole of a footpath trapdoor. This was a gas pipeline adjacent to the Mobil oil pipeline. The consequent explosion and fireball lifted the manhole cover several metres and singed everything in a five-metre radius. Later, Mrs Randall's fourth-class lessons were interrupted by two constables making inquiries about a bomb detonation. They only had to look for the fresh winter tan, lack of eyebrows, singed jumper and smell of smoke and gunpowder.' Andrew Cohen of Glebe also liked to lift the lid: 'Poor old Mr Smith. After two tin letterboxes had succumbed to tuppeny bungers, he installed a big, stylish, sandstone receptacle that he believed impregnable, but four tuppenies bound together lifted the massive lid, rotating skywards then smashing to pieces on his Pymble driveway in 1965.' If bungers were still around, the choko hand grenade would be a luxury, according to Stewart Martin of Mangerton: 'Saw chokos for $7.50/kg at Woolies. Pretty expensive ammo, these days.'
The Age
5 days ago
- General
- The Age
The downside of stocking up
More on the art of obtaining retail rewards (C8) now, with John Dawson of North Parramatta: 'In the early '60s my boss found a 2000-year supply of carbon paper in the stationery cabinet. The supplier used to give a pair of stockings with each box ordered by the stenographer.' 'Simon Dixon (C8) has enthralled us with a token multi-generation breakfast saga,' gushes Warren Finnan of West Ryde. 'We eagerly wait for the next episode in this exciting cereal!' 'Thank you to all those Good Samaritans who came to help my husband when he tripped on uneven tiling on the footpath outside 1 York Street last week,' writes Alison Stewart of Waitara, 'To the very patient lady who tried endlessly to contact triple zero but was told there was up to a two-hour wait! Then to the tattooed, dark-wavy-haired delivery cyclist who ran across the street to secure a taxi to drive hubby to Royal North Shore Hospital. Other office workers who passed by also helped. Thank you to all at RNSH, too.' Like Robert Hosking, Peter Miniutti of Ashbury is a fan of lugging park links: 'During early morning winter walks, filled dog-poo bags (C8) in the hoodie pocket is a wonderful way to keep your hand warm.' Stephen Tait of Rose Bay recalls that a pair of locals, emboldened by the success of obliterating a letterbox (C8) on the way to Woolwich Public School, 'dropped a Tom Thumb down the keyhole of a footpath trapdoor. This was a gas pipeline adjacent to the Mobil oil pipeline. The consequent explosion and fireball lifted the manhole cover several metres and singed everything in a five-metre radius. Later, Mrs Randall's fourth-class lessons were interrupted by two constables making inquiries about a bomb detonation. They only had to look for the fresh winter tan, lack of eyebrows, singed jumper and smell of smoke and gunpowder.' Andrew Cohen of Glebe also liked to lift the lid: 'Poor old Mr Smith. After two tin letterboxes had succumbed to tuppeny bungers, he installed a big, stylish, sandstone receptacle that he believed impregnable, but four tuppenies bound together lifted the massive lid, rotating skywards then smashing to pieces on his Pymble driveway in 1965.' If bungers were still around, the choko hand grenade would be a luxury, according to Stewart Martin of Mangerton: 'Saw chokos for $7.50/kg at Woolies. Pretty expensive ammo, these days.'
News.com.au
19-05-2025
- Climate
- News.com.au
Kitesurfer flown to hospital after being blown into powerlines at Ettalong Beach by strong winds
A kitesurfer has been flown to hospital after strong winds lifted him from a popular beach on the NSW Central Coast, blowing him into powerlines before he landed on the road. Emergency services were called to Ettalong Beach on Monday morning after a man in his 50s was lifted from the surf by the winds – which reached up to 61km/h just after 8.30am – and was thrown into powerlines before landing on the road. He was treated at the scene by paramedics and a CareFlight specialist for laceration injuries. A CareFlight helicopter landed at Lemon Grove Park just after 12pm and transported the man to Royal North Shore Hospital. He remains in a stable condition. It follows the Bureau of Meteorology issuing a severe weather warning for the Mid North Coast and parts of the Hunter Region, with heavy rainfall and damaging winds expected to persist into the week. 'Strong southeasterly winds averaging 50 to 70 km/h, with damaging wind gusts of around 90 km/h are expected over the coastal areas of the Hunter and Mid North Coast, during today and into tomorrow,' the warning reads.
Yahoo
19-05-2025
- Climate
- Yahoo
Horror as kitesurfer blown into power lines
A kitesurfer has been flown to hospital after strong winds lifted him from a popular beach on the NSW Central Coast, blowing him into powerlines before he landed on the road. Emergency services were called to Ettalong Beach on Monday morning after a man in his 50s was lifted from the surf by the winds – which reached up to 61km/h just after 8.30am – and was thrown into powerlines before landing on the road. He was treated at the scene by paramedics and a CareFlight specialist for laceration injuries. A CareFlight helicopter landed at Lemon Grove Park just after 12pm and transported the man to Royal North Shore Hospital. He remains in a stable condition. It follows the Bureau of Meteorology issuing a severe weather warning for the Mid North Coast and parts of the Hunter Region, with heavy rainfall and damaging winds expected to persist into the week. 'Strong southeasterly winds averaging 50 to 70 km/h, with damaging wind gusts of around 90 km/h are expected over the coastal areas of the Hunter and Mid North Coast, during today and into tomorrow,' the warning reads.
Globe and Mail
14-05-2025
- Business
- Globe and Mail
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
-- First patient expected to be dosed during Q2 2025 -- -- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas -- -- Starting dose of 4mg tablet QD (once daily) -- -- First trial site in Australia. Four additional sites planned for Australia, South Korea, and U.S. – -- Australian R&D Tax Incentive refund of up to 48.5% of eligible study-related costs expected -- MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ('Pasithea' or the 'Company'), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas. The study will also assess preliminary anti-tumor activity and help determine a recommended dose for subsequent Phase 2 trials. Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is expected to begin patient enrollment in Q2 2025. Additional clinical trial sites in Australia, South Korea, and the United States are expected to be opened in the coming months. Pasithea has selected Novotech (Australia) Pty Limited as its clinical research organization (CRO) for this trial. The Company is conducting the study through its wholly owned subsidiary in Australia, Pasithea MacroMEK Pty Ltd, and anticipates eligibility for an Australian R&D Tax Incentive with a cash refund of up to 48.5% of the amount spent annually on eligible R&D activities (trial costs) in Australia. Dr. Rebecca Brown, M.D., Ph.D. a member of Pasithea's Scientific Advisory Board and Associate Professor of Neuro Oncology at The University of Alabama at Birmingham commented, 'I am pleased to have collaborated with the Pasithea team on the design of a comprehensive dose exploration and expansion study to assess the safety and tolerability of PAS-004 in adult NF1 patients. In addition to testing the effects of PAS-004 on plexiform neurofibromas, exploratory endpoints will also examine the effects of PAS-004 on cutaneous neurofibromas. The safety profile observed to date in advanced cancer patients is encouraging, and I look forward to seeing that profile translate to the NF1 population.' Dr. Brown added, 'One of the biggest challenges in treating plexiform neurofibromas associated with NF1 is ensuring that patients remain on MEK inhibitor therapy over the long-term. Real-world data shows that a significant proportion of NF1 patients discontinue treatment due to poor tolerability, including high rates of rash and gastrointestinal side effects. PAS-004 is also given as a once daily dose that offers a more convenient regimen than current FDA-approved therapies that are dosed twice a day and which could improve patient compliance.' Dr. Tiago Reis Marques, Pasithea's Chief Executive Officer, said, 'Following our recent financing, including the exercise of certain warrants, Pasithea is now funded to produce initial interim patient data in NF1. The initiation of this clinical trial in NF1, the initial indication we seek FDA marketing approval for, marks an important milestone for Pasithea and for patients living with NF1-related plexiform neurofibromas. Activating our first clinical trial site underscores our commitment to advancing PAS-004 as a potential best-in-class next-generation MEK inhibitor. We are encouraged by the safety and clinical data observed to date in oncology patients and are optimistic that PAS-004's tolerability profile will extend to the NF1 population. Importantly, our existing cancer data has enabled us to begin the NF1 trial at a higher dose than originally contemplated. In addition, we anticipate meaningful cash rebates of eligible trial costs through the Australian R&D Tax Incentive, further enhancing the efficiency of this program.' About the Phase 1/1b Clinical Trial in Adult NF1 Patients The primary objective of the Phase 1/1b study (NCT06961565) is to evaluate the safety and tolerability of PAS-004 when administered for one 28-day treatment cycle in adult NF1 participants with at least one and up to two additional target plexiform neurofibromas (PNs) that are symptomatic and inoperable, incompletely resected, or recurrent. Secondary objectives are (i) to identify the recommended Part B dose ('RPBD') or Maximum Tolerated Dose (MTD) of PAS-004, (ii) to characterize the PK and PD profile of PAS-004, (iii) to evaluate the preliminary efficacy of PAS-004 on target PN volume, (iv) to evaluate the preliminary efficacy of PAS-004 on the size, appearance, and associated symptoms of cutaneous neurofibromas (CNs), and (v) to evaluate the impact of PAS-004 on quality of life ('QOL') and any physical symptoms attributed to the target PN. Experimental objectives are (i) to evaluate the impact of PAS-004 on QOL and any physical symptoms attributed to CNs, (ii) to evaluate the impact of PAS-004 on pain and function attributed to PNs, and (iii) to investigate PAS-004 effects on CN tumor cellular and molecular biology. The trial will be conducted in two parts. In Part A, following a screening period of up to 28 days, up to 24 eligible participants will be enrolled sequentially to receive one of four planned dose levels of PAS-004 tablets (4mg, 8mg, 12 mg, 18mg) in a modified 3+3 design. Part A will identify the recommended RPBD. During Part B, up to 24 eligible participants will be enrolled in parallel to receive one of two planned dose levels of PAS-004 tablets. Participants will be dosed at the RPBD level and at a dose level below the RPBD for up to six continuous 28-day treatment cycles. Part B will identify the recommended phase 2 dose (RP2D). The study is planned to be conducted at five clinical trial sites in Australia, South Korea and the U.S. To learn more about the PAS-004 clinical trial in adults with NF1-associated plexiform neurofibromas, please visit About Pasithea Therapeutics Corp. Pasithea is a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, RASopathies and MAPK pathway driven tumors. Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company's ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company's Phase 1/1b clinical trial of PAS-004 in adult patients with NF1-associated plexiform neurofibromas, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company's current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company's plans, assumptions, expectations, beliefs and objectives, the success of the Company's current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Pasithea Therapeutics Contact
